Bio-Techne (TECH) shares tumbled 5.89% in pre-market trading on Wednesday following the release of its first-quarter fiscal 2026 financial results, which fell short of analysts' expectations. The biotechnology company's disappointing performance has sparked concerns among investors about its growth trajectory.

According to the company's report, Bio-Techne posted an adjusted earnings per share (EPS) of $0.42 for the quarter, narrowly missing the IBES estimate of $0.43. More significantly, the company's revenue came in at $286.555 million, falling well below the anticipated $293.9 million. This shortfall in both earnings and revenue appears to be the primary driver behind the stock's sharp decline.

Despite the market's negative reaction, Bio-Techne did report some positive figures. The company's Q1 net income stood at $38.185 million, with an operating income of $47.658 million and a pretax profit of $47.991 million. However, these results were not enough to offset investor concerns about the missed targets. As the market digests this information, all eyes will be on Bio-Techne's ability to realign with expectations in the coming quarters and restore investor confidence.